Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing compound doai
Reexamination Certificate
2006-03-14
2006-03-14
Ponnaluri, Padmashri (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing compound doai
C514S740000, C514S751000
Reexamination Certificate
active
07012100
ABSTRACT:
Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.
REFERENCES:
patent: 4196202 (1980-04-01), Okada
patent: 4906457 (1990-03-01), Ryan
patent: 4929635 (1990-05-01), Coquelet et al.
patent: 5189212 (1993-02-01), Ruenitz
patent: 5556992 (1996-09-01), Gaboury et al.
patent: 5773460 (1998-06-01), Gaboury et al.
patent: 5856517 (1999-01-01), Huryn et al.
patent: 5877185 (1999-03-01), Kun et al.
patent: 5932515 (1999-08-01), Rourke
patent: 5985837 (1999-11-01), Ritter et al.
patent: 5998160 (1999-12-01), Berens
patent: 6030994 (2000-02-01), Huryn et al.
patent: 6054468 (2000-04-01), Geerts et al.
patent: 6310060 (2001-10-01), Barrett et al.
patent: 6359013 (2002-03-01), Reddy et al.
patent: 2001/0018422 (2001-08-01), Ritter et el.
patent: 2002/0048813 (2002-04-01), Gertler et al.
patent: 0 677 292 (1995-10-01), None
patent: 0 747 389 (1996-12-01), None
patent: 2 284 153 (1995-05-01), None
patent: 2 288 333 (1995-10-01), None
patent: 2 303 790 (1997-03-01), None
patent: 2 312 375 (1997-10-01), None
patent: 91/07166 (1991-05-01), None
patent: 93/24442 (1993-12-01), None
patent: 96/07431 (1996-03-01), None
patent: 96/29067 (1996-09-01), None
patent: 98/58639 (1998-12-01), None
patent: 99/01421 (1999-01-01), None
patent: 01/62708 (2001-08-01), None
patent: 01/85166 (2001-11-01), None
patent: 02/20462 (2002-03-01), None
Mariani et al., “Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation gens: a cDNA microarray analysis,” 2001, Journal of Neuro-Oncology, vol. 53, pp. 161-176.
He et al., “C onstruction and Preliminary Screening of a Human Phage Single-Chain Antibody Library Associated with Gastric Cancer,” Journal of Surgical Research, Feb. 2002, vol. 102, pp. 150-155.
Berens et al., “The role of extracellular matrix in human astrocytoma migration and proliferation studied in a microliter scale assay,” Clin. Exp. Metastasis, 1994, vol. 12, pp. 405-415.
Krammer et al., “Melanoma Cell Adhesion to Basement Membrane Mediated by Integrin-related Complexes,” Cancer Research, Jan. 1989, vol. 49, pp. 393-402.
International Search Report, PCT/US03/17399, mailed Nov. 17, 2005.
Beaudry Christian
Berens Michael E.
Edwards David L.
Avolix Pharmaceuticals, Inc.
Daffer McDaniel LLP
Mewherter Ann Marie
Ponnaluri Padmashri
Shibuya Mark L.
LandOfFree
Cell migration inhibiting compositions and methods and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell migration inhibiting compositions and methods and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell migration inhibiting compositions and methods and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3541951